Our Science

Publications and Presentations

search
Date
Title
October 2021
Outcomes of Oral Ibrexafungerp by Pathogen from Two Open-label Studies of Patients with Serious Fungal Infections (FURI and CARES) TIMM
September 2021
Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis (DOVE)
September 2021
Oral Ibrexafungerp Outcomes in Patients with Oropharyngeal Candidiasis and Esophageal Candidiasis from an Interim Analysis of a Phase 3 Open-label Study (FURI) IDWeek
September 2021
Outcomes of Candida Bone and Joint Infections in Eight Patients from a Phase 3 Open-label Study (FURI) IDWeek
March 2021
A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vitro Activity against Candida auris and Other Clinically Relevant Fungal Isolates Antimicrobial Agents and Chemotherapy Sherman Chu,a,b Lisa Long,a,d Rania Sherif,a,d Thomas S. McCormick,a Katyna Borroto-Esoda,c Stephen Barat,cMahmoud A. Ghannouma,d
March 2021
A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vivo Activity in a Murine Model of Hematogenously Disseminated Candida albicans Antimicrobial Agents and Chemotherapy Sherman Chu,a,b Lisa Long,a,dThomas S. McCormick,a Katyna Borroto-Esoda,c Stephen Baratc Mahmoud A. Ghannouma,d
October 2020
Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI) BD Alexander, OA Cornely, PG Pappas, R Miller, M Johnson, J Vazquez, L Ostrosky-Zeichner, A Spec, R Rautemaa-Richardson, R Krause, GR Thompson, TJ Walsh, CG Morse, JW Sanders, D Andes, GM Lyon, FM Marty, MH Miceli, TF Patterson, M Hoenigl, N Azie, DA Angulo
ID Week
October 2020
Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including Isolates with Elevated MIC’s to Echinocandins N. Azie, K. Borroto-Esoda, D. Angulo
ID Week
June 2020
Delayed Initiation of the Novel Oral Glucan Synthase Inhibitor, Ibrexafungerp, is Effective in a Murine Model of Invasive Candidiasis caused by Candida auris N.P. Wiederhold, L.K. Najvar, R. Jaramillo, M. Olivo, H. Patterson, S. Barat, K. Borroto-Esoda, G. Catano, T.F. Patterson
UT Health San Antonio, South Texas Veterans Health Care System, SCYNEXIS, Inc.
ASM Microbe Online
June 2020
Determination of Antifungal Activity of SCY-078, a Novel Glucan Synthase Inhibitor, Against a broad panel of Rare Pathogenic Fungi M. Ghannoum, L. Long, R. Sherif, F. Z. Abidi, K. Borroto-Esoda, S. Barat, D. Angulo, N. Wiederhold
ASM Microbe Online
< PrevNext >